Anifrolumab is a monoclonal antibody targeting IFNAR1 (the receptor for α, β and ω interferons), being developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. [3
]. Sequence BLAST using the heavy and light chain variable regions of anifrolumab provides 100% matches to sequences patented with application US7662381 [3
]. The sequence matches identify anifrolumab as clone 11E2 in the patent.